Overcoming the challenges now limiting islet transplantation

A sequential, integrated approach

Antonello Pileggi, Lorenzo Cobianchi, Luca A Inverardi, Camillo Ricordi

Research output: Chapter in Book/Report/Conference proceedingConference contribution

42 Citations (Scopus)

Abstract

Steady improvements in islet cell processing technology and immunosuppressive protocols have made pancreatic islet transplantation a clinical reality for the treatment of patients with Type 1 diabetes mellitus (T1DM). Recent trials are showing that improved glycemic metabolic control, prevention of severe hypoglycemia, and better quality of life can be reproducibly achieved after transplantation of allogeneic islets in patients with unstable T1DM. Despite these encouraging results, challenges ahead comprise obtaining adequate islet cells for transplant, enhancing islets engraftment, sustaining b cell mass and function over time, and defining effective immune interventions, among others. In order to overcome the current hurdles to the widespread application of islet transplantation there is a need for implementation of integrated, sequential therapeutic approaches.

Original languageEnglish
Title of host publicationAnnals of the New York Academy of Sciences
Pages383-398
Number of pages16
Volume1079
DOIs
StatePublished - Oct 1 2006

Publication series

NameAnnals of the New York Academy of Sciences
Volume1079
ISSN (Print)00778923
ISSN (Electronic)17496632

Fingerprint

Islets of Langerhans Transplantation
Medical problems
Type 1 Diabetes Mellitus
Islets of Langerhans
Transplants
Immunosuppressive Agents
Homologous Transplantation
Hypoglycemia
Processing
Quality of Life
Technology
Therapeutics

Keywords

  • b cell replacement
  • Bioengineering
  • Cytoprotection
  • Diabetes
  • Immune intervention
  • Immunosuppression
  • Insulin
  • Islet transplantation
  • Pancreas
  • Stem cells
  • Tolerance

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Pileggi, A., Cobianchi, L., Inverardi, L. A., & Ricordi, C. (2006). Overcoming the challenges now limiting islet transplantation: A sequential, integrated approach. In Annals of the New York Academy of Sciences (Vol. 1079, pp. 383-398). (Annals of the New York Academy of Sciences; Vol. 1079). https://doi.org/10.1196/annals.1375.059

Overcoming the challenges now limiting islet transplantation : A sequential, integrated approach. / Pileggi, Antonello; Cobianchi, Lorenzo; Inverardi, Luca A; Ricordi, Camillo.

Annals of the New York Academy of Sciences. Vol. 1079 2006. p. 383-398 (Annals of the New York Academy of Sciences; Vol. 1079).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Pileggi, A, Cobianchi, L, Inverardi, LA & Ricordi, C 2006, Overcoming the challenges now limiting islet transplantation: A sequential, integrated approach. in Annals of the New York Academy of Sciences. vol. 1079, Annals of the New York Academy of Sciences, vol. 1079, pp. 383-398. https://doi.org/10.1196/annals.1375.059
Pileggi A, Cobianchi L, Inverardi LA, Ricordi C. Overcoming the challenges now limiting islet transplantation: A sequential, integrated approach. In Annals of the New York Academy of Sciences. Vol. 1079. 2006. p. 383-398. (Annals of the New York Academy of Sciences). https://doi.org/10.1196/annals.1375.059
Pileggi, Antonello ; Cobianchi, Lorenzo ; Inverardi, Luca A ; Ricordi, Camillo. / Overcoming the challenges now limiting islet transplantation : A sequential, integrated approach. Annals of the New York Academy of Sciences. Vol. 1079 2006. pp. 383-398 (Annals of the New York Academy of Sciences).
@inproceedings{bf064357af564469b550ecdb2d5ed517,
title = "Overcoming the challenges now limiting islet transplantation: A sequential, integrated approach",
abstract = "Steady improvements in islet cell processing technology and immunosuppressive protocols have made pancreatic islet transplantation a clinical reality for the treatment of patients with Type 1 diabetes mellitus (T1DM). Recent trials are showing that improved glycemic metabolic control, prevention of severe hypoglycemia, and better quality of life can be reproducibly achieved after transplantation of allogeneic islets in patients with unstable T1DM. Despite these encouraging results, challenges ahead comprise obtaining adequate islet cells for transplant, enhancing islets engraftment, sustaining b cell mass and function over time, and defining effective immune interventions, among others. In order to overcome the current hurdles to the widespread application of islet transplantation there is a need for implementation of integrated, sequential therapeutic approaches.",
keywords = "b cell replacement, Bioengineering, Cytoprotection, Diabetes, Immune intervention, Immunosuppression, Insulin, Islet transplantation, Pancreas, Stem cells, Tolerance",
author = "Antonello Pileggi and Lorenzo Cobianchi and Inverardi, {Luca A} and Camillo Ricordi",
year = "2006",
month = "10",
day = "1",
doi = "10.1196/annals.1375.059",
language = "English",
isbn = "1573316415",
volume = "1079",
series = "Annals of the New York Academy of Sciences",
pages = "383--398",
booktitle = "Annals of the New York Academy of Sciences",

}

TY - GEN

T1 - Overcoming the challenges now limiting islet transplantation

T2 - A sequential, integrated approach

AU - Pileggi, Antonello

AU - Cobianchi, Lorenzo

AU - Inverardi, Luca A

AU - Ricordi, Camillo

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Steady improvements in islet cell processing technology and immunosuppressive protocols have made pancreatic islet transplantation a clinical reality for the treatment of patients with Type 1 diabetes mellitus (T1DM). Recent trials are showing that improved glycemic metabolic control, prevention of severe hypoglycemia, and better quality of life can be reproducibly achieved after transplantation of allogeneic islets in patients with unstable T1DM. Despite these encouraging results, challenges ahead comprise obtaining adequate islet cells for transplant, enhancing islets engraftment, sustaining b cell mass and function over time, and defining effective immune interventions, among others. In order to overcome the current hurdles to the widespread application of islet transplantation there is a need for implementation of integrated, sequential therapeutic approaches.

AB - Steady improvements in islet cell processing technology and immunosuppressive protocols have made pancreatic islet transplantation a clinical reality for the treatment of patients with Type 1 diabetes mellitus (T1DM). Recent trials are showing that improved glycemic metabolic control, prevention of severe hypoglycemia, and better quality of life can be reproducibly achieved after transplantation of allogeneic islets in patients with unstable T1DM. Despite these encouraging results, challenges ahead comprise obtaining adequate islet cells for transplant, enhancing islets engraftment, sustaining b cell mass and function over time, and defining effective immune interventions, among others. In order to overcome the current hurdles to the widespread application of islet transplantation there is a need for implementation of integrated, sequential therapeutic approaches.

KW - b cell replacement

KW - Bioengineering

KW - Cytoprotection

KW - Diabetes

KW - Immune intervention

KW - Immunosuppression

KW - Insulin

KW - Islet transplantation

KW - Pancreas

KW - Stem cells

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=33845717517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845717517&partnerID=8YFLogxK

U2 - 10.1196/annals.1375.059

DO - 10.1196/annals.1375.059

M3 - Conference contribution

SN - 1573316415

SN - 9781573316415

VL - 1079

T3 - Annals of the New York Academy of Sciences

SP - 383

EP - 398

BT - Annals of the New York Academy of Sciences

ER -